DOCSLIB.ORG

Chapter 5: Important Canine Diseases and How to Treat Them 6 CE Hours

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chapter 5: Important Canine Diseases and How to Treat Them 6 CE Hours Chapter 5: Important Canine Diseases and How to Treat Them 6 CE Hours By: Staff Writer Learning objectives Upon completion of this course, the learner will be able to: and ability to overcome the disease. Table 1 presents an overview of Explain the interaction between host and pathogen. the canine diseases most frequently found during visits to standard Identify canines’ defense mechanisms. veterinary clinics and some of the medications available for their Describe pathogens’ weaknesses and strengths. treatment that are discussed in this course. A comprehensive Identify medication used to treat these diseases. bibliography is provided at the end of this discourse, as well. Diseases In this course we will examine some of the more important diseases preventable by vaccination such as parvo, corona, hepatitis, rabies, affecting dogs. We will review how the disease interacts with dogs’ parainfluenza viruses, Lyme disease, leptospirosis, and kennel cough bodies and what how to strengthen and fortify a dog’s resistance are not included in this course. TABLE 1: OVERVIEW OF MAJOR CANINE DISEASES, SOME TREATMENT OPTIONS DISEASE MEDICATIONS Heartworm Macrolides (macrocyclic lactones), diethylcarbamazine. Flea infestation Advantage II, K9Advantix II, BioSpot, Frontline, Frontline Plus Certifect, FiproGuard. Worm infestation Dog Worms 3, Nemex 2, Pro Wormer 2, Safe-Guard, D-Worm. Joint pain Rimadyl, Tramadol, Metacam, Cosequin DS, Etodolac, Aspirin. Ear infection Zymox Otic, Revolution, Panolog Ointment, Animax. Eye disease Terramycin, Vetericyn, Opticlear. Skin disease Animax, Fungisan, Betadine, Vetericyn, Ketochlor, Panolog, Zymox. Bladder infection Amoxicillin, Zeniquin, Baytril, Cephalosporine, Tetracycline. High blood pressure Amlodipine, Enalapril, Inderal, Tenormin. Giardiasis Ornidazole, Tinidazole, Metronidazole, Nitazoxanide, Albendazole. Heartworm (Dirofilariasis) CAUSE: Dirofilaria Radiography of the thorax will confirm the diagnosis and provide an immitis, a nematode, is indication of the extent and severity of the nematode burden. carried by mosquitoes The disease process goes from: (culex, aedes, ● Stage 1: Early infestation, often asymptomatic with the occasional anopheles, and others) cough. The physical examination, and even radiography, may find as intermediate hosts. nothing. Wild animals (foxes, ● Stage 2: In a more advanced stage, symptoms include dyspnea, wolves, coyotes, some coughing, slowing down, and disinclination to exercise. raccoons, seals, or sea Radiography will show some enlargement of the pulmonary artery lions) may serve as and interstitial lesions. There will be minor anemia and evidence reservoir in of protein in the urine. geographical regions ● Stage 3: Frequent coughing, unwillingness to move and exercise, conducive to the multiplication of mosquitoes. After entering the weight loss, increasing enlargement of the pulmonary artery, often mosquito and only with outside temperatures remaining above 13.9°C affecting the right ventricle of the heart and arteriolar infiltration, (57°F), the microfilaridae develop through Larval Stages 1 and 2 and and pronounced anemia and proteinuria. are passed on as Larval Stage 3 to the next blood donor, usually the ● Stage 4: There may be hundreds of worms invading the heart, dog. In the dog’s subcutaneous and sub-muscular tissues, the worm lungs, and caval veins, obstructing the vasculatory system, which develops to its mature stage (Larval Stage 5) and enters the circulatory results in pronounced dyspnea, tachycardia, anemia, and dark system, ending up in the pulmonary artery and, usually, the right heart hemoglobinuria. The dog may be close to collapse and death. ventricle. The mature male dirofilariae grow to about 6 inches while In a dog without obvious signs of the disease, the presence of a the female may reach more than 1 foot. They may reside in the heart specific antigen will confirm the diagnosis using the Enzyme- and the pulmonary artery for years. Linked ImmunoSorbent Assay (ELISA) procedure. ELISA test kits Diagnosis: Clinical symptoms of the disease include coughing, are available from a variety of manufacturers. They can also be hemoptysis, and epistaxis, breathing difficulties, lethargy and produced in-house. In short, they consist of: unwillingness to move, unthriftiness, cyanosis, fainting, and ascites. veterinarians.elitecme.com Page 42 1. An antibody specific to the antigen that is being looking for, the result of prior preventive treatment and not necessarily indicate fixed onto a surface; absence of active infestation. 2. The antigen to confirm the presence of the antibody (positive Prevention: Prevention of infestation is, obviously, preferable to control), the test sample, and a diluent sample (negative treatment of the established disease. Reducing exposure to mosquito control); bites is a positive step. Prevention is possible by regular application of 3. Diluent to wash off controls and unadhered test sample; macrocyclic lactones, such as Ivermectin, Milbemycin, Moxidectin, 4. Antigen-specific antibody, which has been combined with an and Selamectin (Table 2), followed by appropriate veterinary check- enzyme to indicate the presence of an antigen attached to the ups and serology. Macrolides, derived from Streptomyces Sp., stop known antibody; the development of larvae early after infection, and prevent the further 5. Enzyme substrate to indicate the presence of the enzyme development of microfilariae to the mature female thus breaking the by changing its color (only present when there is a positive nematode’s replication cycle. Preventive treatment should commence antigen residue on the test sample). early in the life of the pup, about 6 to 8 weeks of age, and ideally There are many varieties of this testing procedure in many different continue monthly, year-round. At the very least, it should start 1 month test kits, too many to be discussed in this context. One can expect before the mosquito season and continue until at least 1 month after to detect the antigen with at least three developed female worms, the end of the mosquito threat. In the latter case, and when there was about 6 to 7 months after onset of the infestation. However, if there a chance of an earlier mosquito contact, the animal should be tested are only immature worms or males, there will be no antigen-positive for the presence of dirofilaria antigen or the parasite itself. This is results. In the blood of microfilaremic dogs, one might find circulating important because of the possibility of allergic shock following the microfilariae. To improve chances of finding them, the blood sample destruction of significant numbers of the nematode and its larvae can be centrifuged and the sediment examined microscopically, or subsequent to treatment, thus presenting the host suddenly with large after lysing the blood cell population, the circulating larvae can be amounts of allergenic foreign protein. collected on a filter. Not finding any, on the other hand, may only be TABLE 2: MACROLIDES FOR HEARTWORM PREVENTION BRAND AGENT DOSAGE EFFECTIVENESS Heartgard Ivermectin 6-12 µg/kg/mth/po Heartworm. HeartgardPlus Ivermectin/Pyrantel 6 µg/5 mg per kg/mth/po Heartworm, roundworm, hookworm. Interceptor* Milbemycin oxime 0.5-1 mg/kg/mth/po Heartworm, round-, hook-, whipworm. Sentinel* Milbem. ox./ Lufenuron 0.5-1 mg/kg/mth/po Heartworm, fleas, round-, hook-, whipworm. ProHeart 6* Moxidectin 0.17 mg/kg/6mths/im Heartworm, hookworm. Advantage Multi Imidacloprid/Moxidectin 20 mg/5mg/kg/mth/top Heartworm, fleas, round-, hook-, whipworm. Revolution Selamectin 6-12 mg/kg/mth/top Heartworm, fleas, ticks, mites. * manufacturer suspended production Action of preventatives: Macrolides encompass biologicals with active ingredient of ivermectin, abamectin, doramectin, eprinomectin, macrocyclic lactone rings. They are derived from Streptomyces selamectin, and others. Even low doses are highly effective Sp., an actinobacterium. This group of agents includes, along with against immature dirofilaria both in preventive and treating modes. highly effective antinematodal and insecticidal drugs, antibiotics, Avermectins do not kill the adult worm, although extended prophylaxis antifungals, gastroprokinetics (affecting gastrointestinal motility), and with this drug will clear up the infestation eventually. Prophylactic immunosuppressants. Avermectins and milbemycins, in particular, potency persists for more than a month, justifying the recommended are mentioned here as the most effective means of fighting dirofilaria monthly dosage. nematodes. Avermectin, isolated from Streptomyces avermitilis, is the TABLE 3: HEARTWORM DEVELOPMENTAL PROGRESS Dirofilaria Stages: L1 L2 L3 (infective) L4 Adult Mosquito Host: Mosquito Mosquito Mosquito (labia) - - Canine Host: - - Dog (skin) Abdomen-Thorax Pulmonary/Heart Duration of Growth: 4 wks (2 if amb.T° >27°C) 3-12 days 50-70 days 70-120 days Duration of Existence: 7-9 months 3-5-10 years Treatment: Mosquito Control Macrolides Melarsomine Dosage can be oral, parenteral, or topical. Spreading throughout pH, cell migration, cell proliferation and differentiation, cell volume, the body via any of those routes, it will be concentrated quickly in epithelial fluid secretion and solute transport, smooth muscle action, the fatty connective tissue of skin, gastrointestinal tract, and lungs. and neuro-excitation. Glutamate-gated chloride channels do not Oral dosage can be improved by reducing food intake at the time of exist in mammals, making the activity of this drug
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 8,227,427 B2 Coracci Neto Et Al
    USOO8227427B2 (12) United States Patent (10) Patent No.: US 8,227,427 B2 Coracci Neto et al. (45) Date of Patent: Jul. 24, 2012 (54) VETERINARIAN COMPOSITION (52) US. Cl. ........................................ .. 514/27; 514/368 COMPRISING AN ORGANIC SALT 0F (58) Field of Classi?cation Search ................. .. 513/71; LEVAMISOLE IN COMBINATION WITH AT 548/155; 514/27, 368 LEAST ONE AVERMECTIN AND/OR See application ?le for complete search history. MILBEMYCIN (75) Inventors: Dolivar Coracci Neto, Sertaozinho (56) References Cited (BR); Nelson Henriques Fernandes Filho, Jaboticabal (BR); Ricardo da FOREIGN PATENT DOCUMENTS Silva Sercheli, Jaboticabal (BR) BR PI0505716 A 9/2007 GB 2150024 A 6/1985 (73) Assignee: NPA—Nucleo de Pesquisas Aplicadas WO 00/74489 A1 12/2000 Ltda., Jaboticabal (BR) WO 2004/009080 A1 1/2004 OTHER PUBLICATIONS ( * ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 International Search Report. U.S.C. 154(b) by 575 days. Analytical Report Characterization of Pharmaceutical Input Aurixazol (Feb. 20, 2010). (21) App1.No.: 12/097,683 Primary Examiner * Elli Peselev (22) PCT Filed: Dec. 18, 2006 (74) Attorney, Agent, or Firm * Laurence P. Colton; Smith Risley Tempel Santos LLC (86) PCT No.: PCT/BR2006/000282 § 371 (0X1)’ (57) ABSTRACT (2), (4) Date: Nov. 3, 2008 Veterinarian composition comprising an organic salt of (87) PCT Pub. No.: WO2007/068073 levamisole in combination With at least one avermectin and/ or milbemycin. A veterinarian formulation comprising of organ PCT Pub. Date: Jun. 21, 2007 ics salts of levamisole, more speci?cally to the levamisole salt of 2,6-diiodo-4-nitrophenol and the levamisole salt of 4-hy (65) Prior Publication Data droxy-3-iodo-5-nitrobenzonitrile With avermectins and mil US 2009/0075918 A1 Mar.
    [Show full text]
  • Full Text in Pdf Format
    DISEASES OF AQUATIC ORGANISMS Published July 30 Dis Aquat Org Oral pharmacological treatments for parasitic diseases of rainbow trout Oncorhynchus mykiss. 11: Gyrodactylus sp. J. L. Tojo*, M. T. Santamarina Department of Microbiology and Parasitology, Laboratory of Parasitology, Faculty of Pharmacy, Universidad de Santiago de Compostela, E-15706 Santiago de Compostela, Spain ABSTRACT: A total of 24 drugs were evaluated as regards their efficacy for oral treatment of gyro- dactylosis in rainbow trout Oncorhj~nchusmykiss. In preliminary trials, all drugs were supplied to infected fish at 40 g per kg of feed for 10 d. Twenty-two of the drugs tested (aminosidine, amprolium, benznidazole, b~thionol,chloroquine, diethylcarbamazine, flubendazole, levamisole, mebendazole, n~etronidazole,mclosamide, nitroxynil, oxibendazole, parbendazole, piperazine, praziquantel, roni- dazole, secnidazole, tetramisole, thiophanate, toltrazuril and trichlorfon) were ineffective Triclabenda- zole and nitroscanate completely eliminated the infection. Triclabendazole was effective only at the screening dosage (40 g per kg of feed for 10 d), while nitroscanate was effective at dosages as low as 0.6 g per kg of feed for 1 d. KEY WORDS: Gyrodactylosis . Rainbow trout Treatment. Drugs INTRODUCTION to the hooks of the opisthohaptor or to ulceration as a result of feeding by the parasite. The latter is the most The monogenean genus Gyrodactylus is widespread, serious. though some individual species have a restricted distri- Transmission takes place largely as a result of direct bution. Gyrodactyloses affect numerous freshwater contact between live fishes, though other pathways species including salmonids, cyprinids and ornamen- (contact between a live fish and a dead fish, or with tal fishes, as well as marine fishes including gadids, free-living parasites present in the substrate, or with pleuronectids and gobiids.
    [Show full text]
  • Comparative Efficacies of Commercially Available Benzimidazoles Against Pseudodactylogyrus Infestations in Eels
    DISEASES OF AQUATIC ORGANISMS Published October 4 Dis. aquat. Org. l Comparative efficacies of commercially available benzimidazoles against Pseudodactylogyrus infestations in eels ' Department of Fish Diseases, Royal Veterinary and Agricultural University, 13 Biilowsvej, DK-1870 Frederiksberg C, Denmark Department of Pharmacy, Royal Veterinary and Agricultural University, 13 Biilowsvej. DK-1870 Frederiksberg C,Denmark ABSTRACT: The antiparasitic efficacies of 9 benzimidazoles in commercially avalable formulations were tested (water bath treatments) on small pigmented eels Anguilla anguilla, expenmentally infected by 30 to 140 specimens of Pseudodactylogyrus spp. (Monogenea).Exposure time was 24 h and eels were examined 4 to 5 d post treatment. Mebendazole (Vermox; 1 mg 1-') eradicated all parasites, whereas luxabendazole (pure substance) and albendazole (Valbazen) were 100 % effective only at a concen- tration of 10 mg I-'. Flubendazole (Flubenol), fenbendazole (Panacur) and oxibendazole (Lodltac) (10 mg l-') caused a reduction of the infection level to a larger extent than did triclabendazole (Fasinex) and parbendazole (Helmatac).Thiabendazole (Equizole), even at a concentration as high as 100 mg l-', was without effect on Pseudodactylogyrus spp. INTRODUCTION range of commercially available benzimidazole com- pounds. If drug resistance will develop under practical The broad spectrum anthelmintic drug mebendazoIe eel-farm conditions in the future, it is likely to be was reported as an efficacious compound against infes- recognized during treatments with commercially avail- tations of the European eel Anguilla anguilla with gill able drug formulations. Therefore this type of drug parasitic monogeneans of the genus Pseudodactylo- preparations were used in the present study. gyms (Szekely & Molnar 1987, Buchmann & Bjerre- gaard 1989, 1990, Mellergaard 1989).
    [Show full text]
  • Bulletin Leading the Fight Against Heartworm Disease
    BULLETIN LEADING THE FIGHT AGAINST HEARTWORM DISEASE SEPTEMBER HEARTWORM 2017 Q&A VOLUME 44 No. 3 Heartworm History: In What Year Was Heartworm First INSIDE THIS ISSUE Treated? Page 4 From the President Page 8 Research Update Abstracts from the Literature Page 14 Heartworm Hotline: Role of Heat Treatment in Diagnostics Page 19 NEW! Best Practices: Minimizing Heartworm Transmission in Relocated Dogs uestions from members, prac- published in the 1998 AHS Symposium 1 titioners, technicians, and the Proceedings. Dr. Roncalli wrote, “The Page 21 Qgeneral public are often submit- first trial to assess the efficacy of a Welcome Our New AHS ted to the American Heartworm Society microfilaricide (natrium antimonyl tar- Student Liaisons (AHS) via our website. Two of our AHS trate) was conducted some 70 years Board members, Dr. John W.McCall and ago (1927) in Japan by S. Itagaki and R. Page 25 Dr. Tom Nelson, provided the resources Makino.2 Fuadin (stibophen), a trivalent In the News: Surgeons to answer this question: In What Year antimony compound, was tested, intra- Remove a Heartworm from Was Heartworm First Treated? venously, as a microfilaricide by Popescu the Femoral Artery of a Cat The first efforts to treat canine heart- in 1933 in Romania and by W.H. Wright worm disease date back to the 1920s. Dr. and P.C. Underwood in 1934 in the USA. Page 26 Nelson referenced a review article by Dr. In 1949, I.C. Mark evaluated its use Quarterly Update Raffaele Roncalli, “Tracing the History of intraperitoneally.” What’s New From AHS? Heartworms: A 400 Year Perspective,” Continues on page 7 American Heartworm Society / PO Box 8266, Wilmington, DE 19803-8266 Become an American Heartworm Society www.heartwormsociety.org / [email protected] fan on Facebook! Follow us on Twitter! OUR GENEROUS SPONSORS PLATINUM LEVEL PO Box 8266 Wilmington, DE 19803-8266 [email protected] www.heartwormsociety.org Mission Statement The mission of the American Heartworm Society is to lead the vet- erinary profession and the public in the understanding of heartworm disease.
    [Show full text]
  • Baylisascariasis
    Baylisascariasis Importance Baylisascaris procyonis, an intestinal nematode of raccoons, can cause severe neurological and ocular signs when its larvae migrate in humans, other mammals and birds. Although clinical cases seem to be rare in people, most reported cases have been Last Updated: December 2013 serious and difficult to treat. Severe disease has also been reported in other mammals and birds. Other species of Baylisascaris, particularly B. melis of European badgers and B. columnaris of skunks, can also cause neural and ocular larva migrans in animals, and are potential human pathogens. Etiology Baylisascariasis is caused by intestinal nematodes (family Ascarididae) in the genus Baylisascaris. The three most pathogenic species are Baylisascaris procyonis, B. melis and B. columnaris. The larvae of these three species can cause extensive damage in intermediate/paratenic hosts: they migrate extensively, continue to grow considerably within these hosts, and sometimes invade the CNS or the eye. Their larvae are very similar in appearance, which can make it very difficult to identify the causative agent in some clinical cases. Other species of Baylisascaris including B. transfuga, B. devos, B. schroeder and B. tasmaniensis may also cause larva migrans. In general, the latter organisms are smaller and tend to invade the muscles, intestines and mesentery; however, B. transfuga has been shown to cause ocular and neural larva migrans in some animals. Species Affected Raccoons (Procyon lotor) are usually the definitive hosts for B. procyonis. Other species known to serve as definitive hosts include dogs (which can be both definitive and intermediate hosts) and kinkajous. Coatimundis and ringtails, which are closely related to kinkajous, might also be able to harbor B.
    [Show full text]
  • Mebendazole 1
    The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/625/99-FINAL July 1999 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS MEBENDAZOLE SUMMARY REPORT (1) 1. Mebendazole is a benzimidazole anthelmintic which is used in both human and veterinary medicine. In veterinary medicine, it is administered orally to horses, at a target dose of 8.8 mg/kg bw and to sheep and goats at a target dose of 15 mg/kg bw. Mebendazole has also been used in game birds, pigs, deer, poultry and cattle, including lactating animals and laying birds, but these uses were not supported with regard to the establishment of MRLs. Mebendazole is authorised in a range of mono-preparations including premixes for medicated feed, pastes, tablets, liquids, granules, drenches and suspensions for oral administration. Mebendazole is also used in combination products additionally containing either metrifonate, closantel or minerals (selenium, cobalt). 2. The pharmacokinetics of mebendazole was studied in rats, mice, dogs, humans and several target species. In rats given oral doses in the range of 0.06 to 10 mg/kg bw 14C-mebendazole, most of the radioactivity was recovered from the organs of the gastrointestinal tract and consisted mostly of unmetabolised mebendazole. Less than 1% of the administered radioactivity was detected in blood. Excretion was predominantly via the faeces, with 70 to 90% of the faecal radioactivity consisting of unmetabolised mebendazole. In rat liver, 1 hour after administration, 15% of the radioactivity consisted of unmetabolised mebendazole. Four hours after administration, the percentage of mebendazole had declined to 1%. Absorption in humans was increased when the same dose was given with a meal.
    [Show full text]
  • (12) 按照专利合作条约所公布的国际申请w O 2016/062277
    卜 (12) 按照专利合作条约所公布的国际申请 (19) 世界知识 组织 国 际 局 (10) 国际公布号 (43) 国际公布 日 W O 2016/062277 A 1 2016 年 4 月 28 日 （28.04.2016) W P O P C T (51) 国转 利分类号： (74) 代理人 : 北京元本知识产权代理事务所 (BEIJING A61K 31/7048 (2 6 A61K 31/4985 (2006.01) Y U A B E N INTELLECTUAL PROPERTY LAW O F A61K 31/4184 (2006.01) A61K 31/00 (2006.01) FICE); 中 国北 京 市 海 淀 区花 园路 12 号 时代 玉 成 A61K 31/415 (2006.01) A61P 35/00 (2006.01) 403, Beijing 100088 (CN ) 。 A61K 31/429 (2006.01) (81) 指定国 （除另有指 明，要求每一种可提供 的国家保 (21) 国际申请号： PCT/CN20 15/092746 护 ）：AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, (22) 国际申请 曰： 2015 年 10 月 23 日 （23. 10.2015) CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, (25) 申请语言： 中文 GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, (26) 公布语言： 中文 LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, (30) 优先权： RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, 62/068,298 2014 年 10 月 24 日 （24. 10.2014) U S SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, (71) 申请 人 ：朗齐生物 医学股份有 限公司 （LAUNX VC, VN, ZA, ZM, Z BIOMEDICAL CO., LTD.) [CN/CN]; 中 国台湾 省 高 (84) 指定国 （除另有指 明，要求每一种可提供 的地 区保 雄 市 前 金 区 自强 一 路 32 巷 1 号 2 楼 ，Taiwan 801 护）：ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, (CN) RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), 欧亚 （AM, AZ, (72) 发明人 : 陈丘泓 (CHEN, Chiu-Hung); 中国台湾省高 BY, KG, KZ, RU, TJ, TM), ：洲 (AL, AT, BE, BG, CH, 雄 市前金 区 自强一路 32 巷 1 号，Taiwan 801 (CN) 。 CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, 庄秀 (CHUANG, Show-Mei); 国台湾 省 台 中市 IS,
    [Show full text]
  • Chemotherapy of Gastrointestinal Helminths
    Chemotherapy of Gastrointestinal Helminths Contributors J. H. Arundel • J. H. Boersema • C. F. A. Bruyning • J. H. Cross A. Davis • A. De Muynck • P. G. Janssens • W. S. Kammerer IF. Michel • M.H. Mirck • M.D. Rickard F. Rochette M. M. H. Sewell • H. Vanden Bossche Editors H. Vanden Bossche • D.Thienpont • P.G. Janssens UNIVERSITATS- BlfiUOTHElC Springer-Verlag Berlin Heidelberg New York Tokyo Contents CHAPTER 1 Introduction. A. DAVIS A. Pathogenic Mechanisms in Man 1 B. Modes of Transmission 2 C. Clinical Sequelae of Infection 3 D. Epidemiological Considerations 3 E. Chemotherapy 4 F. Conclusion 5 References 5 CHAPTER 2 Epidemiology of Gastrointestinal Helminths in Human Populations C. F. A. BRUYNING A. Introduction 7 B. Epidemiological or "Mathematical" Models and Control 8 C. Nematodes 11 I. Angiostrongylus costaricensis 11 II. Anisakis marina 12 III. Ascaris lumbricoides 14 IV. Capillaria philippinensis 21 V. Enterobius vermicularis 23 VI. Gnathostoma spinigerum 25 VII. Hookworms: Ancylostoma duodenale and Necator americanus . 26 VIII. Oesophagostoma spp 32 IX. Strongyloides stercoralis 33 X. Ternidens deminutus 34 XI. Trichinella spiralis 35 XII. Trichostrongylus spp 38 XIII. Trichuris trichiura 39 D. Trematodes 41 I. Echinostoma spp 41 II. Fasciolopsis buski 42 III. Gastrodiscoides hominis 44 IV. Heterophyes heterophyes 44 V. Metagonimus yokogawai 46 X Contents E. Cestodes 47 I. Diphyllobothrium latum 47 II. Dipylidium caninum 50 III. Hymenolepis diminuta 51 IV. Hymenolepis nana 52 V. Taenia saginata 54 VI. Taenia solium 57 VII. Cysticercosis cellulosae 58 References 60 CHAPTER 3 Epidemiology and Control of Gastrointestinal Helminths in Domestic Animals J. F. MICHEL. With 20 Figures A. Introduction 67 I.
    [Show full text]
  • Veterinary Guide to Resistance & Parasites
    Veterinary Guide to Resistance & Parasites How to make the Get Rotation Right deworming strategy part of your equine health wellness protocol. ||||||||||||||||||||||||||||||||||||||||| GET ROTATION RIGHT Resistant parasites – veterinary involvement is needed now. Deworming has come a long way in the past 50 years – from products that were nearly toxic and required complicated tubing to the easy-to-administer dewormers we know now. As more horse owners recognize the value of regular deworming, past troublemakers such as large strongyles have become much less of a threat. Still, deworming is nothing to take lightly. As internal parasites become more resistant, your expertise is needed Horseowners unknowingly more than ever to make sure deworming programs remain efficient contribute to resistance. and effective. Only with veterinary involvement will we control parasite • Rotating brand names, not populations, combat resistance and get rotation right. chemical classes – general confusion about when and RESISTANCE IS REAL: MULTIPLE DRUGS, MULTIPLE PARASITES. how to use different classes • No new drug class since avermectins in 1981. of dewormers. • Benzimidazole resistance in cyathostomes.1-3 • Lack of knowledge about • Pyrantel resistance in cyathostomes and ascarids.4-8,11 resistance issues. • Ivermectin and moxidectin resistance among ascarids.8,9,11 • Deworming many horses more • Early warning signs of macrocyclic-lactone-resistant cyathostomes.10 frequently than necessary. • Health-related issues caused by parasites: • Misunderstanding about the ~ Ascarids (roundworms) unique properties of larvicidal Verminous pneumonia: cough, nasal discharge, low-grade fever treatments and how to maximize Unthriftiness – rough hair coat their efficacy. Intestinal obstruction/colic • Underdosing their horses. Intestinal perforation leading to peracute death Decreased performance and reduced weight gain ~ Cyathostomes (small strongyles) Most common in young and old horses, but can afflict any horse.
    [Show full text]
  • Anthelmintic Resistance of Ostertagia Ostertagi and Cooperia Oncophora to Macrocyclic Lactones in Cattle from the Western United States
    Veterinary Parasitology 170 (2010) 224–229 Contents lists available at ScienceDirect Veterinary Parasitology journal homepage: www.elsevier.com/locate/vetpar Anthelmintic resistance of Ostertagia ostertagi and Cooperia oncophora to macrocyclic lactones in cattle from the western United States M.D. Edmonds, E.G. Johnson, J.D. Edmonds ∗ Johnson Research LLC, 24007 Highway 20-26, Parma, ID, 83660, USA article info abstract Article history: In June 2008, 122 yearling heifers with a history of anthelmintic resistance were obtained Received 15 October 2009 from pastures in northern California and transported to a dry lot facility in southwest- Received in revised form 28 January 2010 ern Idaho, USA. Fifty heifers with the highest fecal egg counts were selected for study Accepted 24 February 2010 enrollment. Candidates were equally randomized to treatment with either injectable iver- mectin (Ivomec®, Merial, 0.2 mg kg−1 BW), injectable moxidectin (Cydectin®, Fort Dodge, Keywords: 0.2 mg kg−1 BW), oral fenbendazole (Safe-Guard®, Intervet, 5.0 mg kg−1 BW), oral oxfenda- Anthelmintic resistance zole (Synanthic®, Fort Dodge, 4.5 mg kg−1 BW), or saline. At 14 days post-treatment, Cattle Bovine nematodes were recovered from the abomasum, small intestine, and large intestine. Par- Nematodes asitism was confirmed in the control group when 10/10 animals were infected with Efficacy adult Ostertagia ostertagi and 9/10 animals with both developing and early L4 stages of Cooperia O. ostertagi. Similarly, 9/10 animals were parasitized with adult Cooperia spp. Fenbenda- Ostertagia zole and oxfendazole efficacy verses controls were >90% against adult Cooperia spp., while moxidectin caused an 88% parasite reduction post-treatment (P < 0.05).
    [Show full text]
  • WSAVA List of Essential Medicines for Cats and Dogs
    The World Small Animal Veterinary Association (WSAVA) List of Essential Medicines for Cats and Dogs Version 1; January 20th, 2020 Members of the WSAVA Therapeutic Guidelines Group (TGG) Steagall PV, Pelligand L, Page SW, Bourgeois M, Weese S, Manigot G, Dublin D, Ferreira JP, Guardabassi L © 2020 WSAVA All Rights Reserved Contents Background ................................................................................................................................... 2 Definition ...................................................................................................................................... 2 Using the List of Essential Medicines ............................................................................................ 2 Criteria for selection of essential medicines ................................................................................. 3 Anaesthetic, analgesic, sedative and emergency drugs ............................................................... 4 Antimicrobial drugs ....................................................................................................................... 7 Antibacterial and antiprotozoal drugs ....................................................................................... 7 Systemic administration ........................................................................................................ 7 Topical administration ........................................................................................................... 9 Antifungal drugs .....................................................................................................................
    [Show full text]
  • WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/107 (2006.01) A61K 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A 61 47/10 (2006.0V) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/US2012/034361 HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 20 April 2012 (20.04.2012) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/480,259 28 April 201 1 (28.04.201 1) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant (for all designated States except US): BOARD UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, OF REGENTS, THE UNIVERSITY OF TEXAS SYS¬ TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, TEM [US/US]; 201 West 7th St., Austin, TX 78701 (US).
    [Show full text]